CDK4 and triple-negative breast carcinoma: A furyl derivative of palbociclib (Figure 5A) exhibited the highest potency against the MDA-MB-453 cell line (triple-negative breast cancer) cell line, preserved selectivity to CDK4/6, and exhibited better stability in the mouse liver microsome assay than palbociclib [100].